| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1008155992 |
| P356 | DOI | 10.1038/NM0103-135 |
| P698 | PubMed publication ID | 12514727 |
| P2093 | author name string | Thomas J Wickham | |
| P2860 | cites work | Genes expressed in human tumor endothelium | Q24290105 |
| HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses | Q24312224 | ||
| Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5 | Q28303765 | ||
| Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment | Q29615852 | ||
| Phage display of adenovirus type 5 fiber knob as a tool for specific ligand selection and validation | Q30685512 | ||
| Targeting human T cells by retroviral vectors displaying antibody domains selected from a phage display library | Q30840200 | ||
| Molecular engineering of matrix-targeted retroviral vectors incorporating a surveillance function inherent in von Willebrand factor | Q30870658 | ||
| Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105). | Q30992933 | ||
| Dressing up adenoviruses to modify their tropism.. Interview by Florence Paillard | Q31431773 | ||
| Modification of an adenoviral vector with biologically selected peptides: a novel strategy for gene delivery to cells of choice | Q56896435 | ||
| A gene delivery system activatable by disease-associated matrix metalloproteinases | Q73254121 | ||
| In vivo selection of protease cleavage sites from retrovirus display libraries | Q31992300 | ||
| Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells | Q33808695 | ||
| A TVA-single-chain antibody fusion protein mediates specific targeting of a subgroup A avian leukosis virus vector to cells expressing a tumor-specific form of epidermal growth factor receptor | Q33811568 | ||
| Targeting avian leukosis virus subgroup A vectors by using a TVA-VEGF bridge protein | Q33837118 | ||
| Targeting adenovirus | Q33837127 | ||
| "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung | Q33841039 | ||
| Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions | Q33849565 | ||
| Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells | Q34090326 | ||
| Pulmonary collectins and innate host defense of the lung | Q34184446 | ||
| Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product | Q34332885 | ||
| Design and gene delivery activity of modified polyethylenimines. | Q34463671 | ||
| Targeting tumors with non-viral gene delivery systems. | Q34608716 | ||
| Adeno-associated virus capsids displaying immunoglobulin-binding domains permit antibody-mediated vector retargeting to specific cell surface receptors | Q34998573 | ||
| Retroviral retargeting by envelopes expressing an N-terminal binding domain. | Q35848344 | ||
| Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types | Q36437996 | ||
| Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors | Q38298395 | ||
| Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids | Q38299901 | ||
| Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen | Q39605575 | ||
| Targeting adenoviral vectors by using the extracellular domain of the coxsackie-adenovirus receptor: improved potency via trimerization | Q39682554 | ||
| Adenovirus binding to the coxsackievirus and adenovirus receptor or integrins is not required to elicit brain inflammation but is necessary to transduce specific neural cell types | Q39682986 | ||
| Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. | Q39882081 | ||
| Retroviral vectors displaying functional antibody fragments | Q40405683 | ||
| Collectins and viral infection | Q40466999 | ||
| Targeting retroviral vector infection to cells that express heregulin receptors using a TVA-heregulin bridge protein | Q40746884 | ||
| Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo | Q40782543 | ||
| Lesion-targeted injectable vectors for vascular restenosis | Q40794373 | ||
| Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts | Q40910125 | ||
| PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery | Q40931003 | ||
| Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'gamma)2 antibody | Q40969562 | ||
| Antiviral activity of bovine collectins against rotaviruses. | Q41007198 | ||
| Development of novel cell surface CD34-targeted recombinant adenoassociated virus vectors for gene therapy | Q41008247 | ||
| Targeting retroviral vectors to vascular lesions by genetic engineering of the MoMLV gp70 envelope protein | Q41068477 | ||
| Targeted gene delivery by tropism-modified adenoviral vectors | Q41152060 | ||
| Tissue-specific targeting of retroviral vectors through ligand-receptor interactions | Q41428152 | ||
| Retroviral display of functional binding domains fused to the amino terminus of influenza hemagglutinin. | Q41482419 | ||
| Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. | Q42609041 | ||
| Masking of retroviral envelope functions by oligomerizing polypeptide adaptors. | Q42798495 | ||
| Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. | Q43583253 | ||
| Tumor regression by targeted gene delivery to the neovasculature | Q44044889 | ||
| Cell-specific targeting of Sindbis virus vectors displaying IgG-binding domains of protein A. | Q45761208 | ||
| Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors | Q45862326 | ||
| Targeting an adenoviral gene vector to cytokine-activated vascular endothelium via E-selectin | Q45862541 | ||
| A blood-tumor barrier limits gene transfer to experimental liver cancer: the effect of vasoactive compounds. | Q45872992 | ||
| Systemic administration of a matrix-targeted retroviral vector is efficacious for cancer gene therapy in mice | Q45874393 | ||
| Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic application | Q45877889 | ||
| Targeting endothelium for gene therapy via receptors up-regulated during angiogenesis and inflammation | Q45885138 | ||
| Tumor-targeted gene delivery of tumor necrosis factor-alpha induces tumor necrosis and tumor regression without systemic toxicity | Q45888026 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 135-139 | |
| P577 | publication date | 2003-01-01 | |
| P1433 | published in | Nature Medicine | Q1633234 |
| P1476 | title | Ligand-directed targeting of genes to the site of disease | |
| P478 | volume | 9 |
| Q40601208 | 5-Fluorocytosine increases the toxicity of Wnt-targeting replicating adenoviruses that express cytosine deaminase as a late gene |
| Q34808441 | A strategy for systemic delivery of the oncolytic herpes virus HSV1716: redirected tropism by antibody-binding sites incorporated on the virion surface as a glycoprotein D fusion protein |
| Q44753959 | Ablating CAR and integrin binding in adenovirus vectors reduces nontarget organ transduction and permits sustained bloodstream persistence following intraperitoneal administration |
| Q45862614 | Adenoviral gene therapy, radiation, and prostate cancer. |
| Q35976811 | Adenovirus protein IX: a new look at an old protein |
| Q36535456 | Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo |
| Q36315685 | Affinity thresholds for membrane fusion triggering by viral glycoproteins |
| Q33230607 | Alteration and analyses of viral entry with library-derived peptides |
| Q42812872 | Analysis of adenovirus gene transfer into adult neural stem cells |
| Q91737511 | Anti-angiogenic treatment of endometriosis via anti-VEGFA siRNA delivery by means of peptide-based carrier in a rat subcutaneous model |
| Q38532388 | Antibody-mediated targeted gene transfer of helper virus-free HSV-1 vectors to rat neocortical neurons that contain either NMDA receptor 2B or 2A subunits |
| Q39685068 | Antibody-mediated targeted gene transfer to NMDA NR1-containing neurons in rat neocortex by helper virus-free HSV-1 vector particles containing a chimeric HSV-1 glycoprotein C-staphylococcus A protein |
| Q40023775 | Augmented transgene expression in transformed cells using a parvoviral hybrid vector |
| Q36509477 | Characterization of a neuraminidase-deficient influenza a virus as a potential gene delivery vector and a live vaccine |
| Q58235086 | Construction of hydroxypropyl-β-cyclodextrin copolymer nanoparticles and targeting delivery of paclitaxel |
| Q37256658 | Coronavirus genetically redirected to the epidermal growth factor receptor exhibits effective antitumor activity against a malignant glioblastoma |
| Q39976098 | Diffusion-limited binding explains binary dose response for local arterial and tumour drug delivery |
| Q37451635 | Drug releasing systems in cardiovascular tissue engineering |
| Q33782857 | Early steps of clathrin-mediated endocytosis involved in phagosomal escape of Fcgamma receptor-targeted adenovirus |
| Q40055904 | Engineering of a stable retroviral gene delivery vector by directed evolution |
| Q33327584 | Enhanced nigrostriatal neuron-specific, long-term expression by using neural-specific promoters in combination with targeted gene transfer by modified helper virus-free HSV-1 vector particles |
| Q33911962 | Envelope targeting: hemagglutinin attachment specificity rather than fusion protein cleavage-activation restricts Tupaia paramyxovirus tropism. |
| Q24623803 | Four viruses, two bacteria, and one receptor: membrane cofactor protein (CD46) as pathogens' magnet |
| Q36769984 | Functionalized micellar systems for cancer targeted drug delivery |
| Q35156511 | Gene therapeutic approaches for medullary thyroid carcinoma treatment. |
| Q91584294 | Gene therapy for thyroid cancer |
| Q35165719 | Gene therapy progress and prospects: adenoviral vectors |
| Q40581107 | HSV-1 virions engineered for specific binding to cell surface receptors |
| Q33555864 | Heart-targeted adeno-associated viral vectors selected by in vivo biopanning of a random viral display peptide library |
| Q45496884 | Herpes simplex virus targeting to the EGF receptor by a gD-specific soluble bridging molecule |
| Q33288346 | Identification of a retroviral receptor used by an envelope protein derived by peptide library screening |
| Q37895969 | Immunotherapeutic potential of oncolytic vaccinia virus |
| Q40350503 | Infectivity enhancement for adenoviral transduction of canine osteosarcoma cells |
| Q37115390 | Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery. |
| Q47767932 | Molecular mechanism of caspase-3-induced gene expression of polyplexes formed from polycations grafted with cationic substrate peptides. |
| Q39017324 | Multifunctional nanoassemblies of block copolymers for future cancer therapy |
| Q36316859 | On the delivery of small interfering RNAs into mammalian cells |
| Q35902523 | Oncolytic viruses for the treatment of cancer: current strategies and clinical trials. |
| Q38020107 | Oncolytic viruses in the treatment of cancer: a review of current strategies |
| Q28476268 | Optimizing targeted gene delivery: chemical modification of viral vectors and synthesis of artificial virus vector systems |
| Q37211504 | Polymeric micelles from poly(ethylene glycol)-poly(amino acid) block copolymer for drug and gene delivery |
| Q46862788 | Preparation of poly(ethylene glycol)-introduced cationized gelatin as a non-viral gene carrier |
| Q81348398 | Rescue and propagation of fully retargeted oncolytic measles viruses |
| Q40670694 | Soluble receptor-mediated targeting of mouse hepatitis coronavirus to the human epidermal growth factor receptor |
| Q33428576 | Successful expansion but not complete restriction of tropism of adeno-associated virus by in vivo biopanning of random virus display peptide libraries |
| Q35575232 | Synthesis of polysaccharide-block-polypeptide copolymer for potential co-delivery of drug and plasmid DNA. |
| Q40402866 | Targeted gene transfer to nigrostriatal neurons in the rat brain by helper virus-free HSV-1 vector particles that contain either a chimeric HSV-1 glycoprotein C-GDNF or a gC-BDNF protein |
| Q40416025 | Targeting Sindbis virus-based vectors to Fc receptor-positive cell types |
| Q36293332 | Targeting of polyplexes: toward synthetic virus vector systems |
| Q40619723 | The effect of sequestration by nontarget tissues on anti-tumor efficacy of systemically applied, conditionally replicating adenovirus vectors. |
| Q37804497 | The next step in gene delivery: Molecular engineering of adeno-associated virus serotypes |
| Q35649591 | Treatment of multifocal breast cancer by systemic delivery of dual-targeted adeno-associated viral vectors. |
| Q44848779 | Use of adenovirus protein IX (pIX) to display large polypeptides on the virion--generation of fluorescent virus through the incorporation of pIX-GFP. |
| Q34315475 | Viral and nonviral delivery systems for gene delivery |
| Q45862358 | Virology and immunology of gene therapy, or virology and immunology of high MOI infection with defective viruses |
| Q36254857 | Viruses with deletions in antiapoptotic genes as potential oncolytic agents. |
| Q37087304 | With a little help from my f(X)riends!: the basis of Ad5-mediated transduction of the liver revealed |
Search more.